Results 191 to 200 of about 4,786,755 (237)

A retrospective real-world study assessing diagnostic pattern of light-chain amyloidosis in Japan based on data from the medical data vision claims database. [PDF]

Ther Adv Hematol
Yogo M, Kasahara-Kiritani M, Oshima K, Ishida T.   +3 more
europepmc   +1 more source

The Association of Kidney Function on Survival in Patients with Amyloid Light Chain Amyloidosis after Autologous Stem Cell Transplantation: A Multicenter Study. [PDF]

Kidney360
Selamet U, Joachim K, Lin H, Rondon G, Martinez CS, Delgado R, Page V, Motwani SS, Dincer B, Bianchi G, Qazilbash M, Murakami N, Abudayyeh A.   +12 more
europepmc   +1 more source

Renal heavy and light chain amyloidosis: A rare case report. [PDF]

Medicine (Baltimore)
Chen B, Wang J, Zang W, Wang C, Li J, Yang R.   +5 more
europepmc   +1 more source

Immunoglobulin light chain amyloidosis

Expert Review of Hematology, 2013
Primary light chain amyloidosis is the most common form of systemic amyloidosis and is caused by misfolded light chains that cause proteotoxicity and rapid decline of vital organ function. Early diagnosis is essential in order to deliver effective therapy and prevent irreversible organ damage.
MERLINI, GIAMPAOLO, Comenzo RL, Seldin DC, Wechalekar A, Gertz MA   +4 more
openaire   +4 more sources

Amyloidosis and Light Chain Plasmocytoma

Tumori Journal, 1976
Nine cases of light chain plasmocytomas, 6 type λ and 3 type k, have been studied in reference to amyloid presence and localisation. Bone marrow plasmocytosis, light chains in serum and/or in the urine, and osteolytic lesions were demonstrated in all the patients.
G, Tosato, E, Fagiolo
openaire   +3 more sources

Some of the next articles are maybe not open access.

Related searches:

Advances in the treatment of light chain amyloidosis

Current Opinion in Oncology, 2022
Purpose of review After many years, the management of systemic light chain (AL) amyloidosis is entering the era of evidence-based medicine, with three recently published randomized clinical trials, a regimen (daratumumab, cyclophosphamide, bortezomib, and dexamethasone, daratumumab-CyBorD) labeled for upfront therapy, more ...
Palladini, Giovanni, Milani, Paolo
openaire   +3 more sources

Coagulation Abnormalities in Light Chain Amyloidosis

Mayo Clinic Proceedings, 2021
To assess the prevalence of coagulation abnormalities in patients with systemic light chain (AL) amyloidosis and their association with disease-related characteristics, disease progression, and survival.This is a retrospective study of patients with AL amyloidosis seen at Mayo Clinic, Rochester, Minnesota, from January 1, 2006, to December 31, 2015. We
Nadine Abdallah, Eli Muchtar, Angela Dispenzieri, Wilson Gonsalves, Francis Buadi, Martha Q. Lacy, Suzanne R. Hayman, Taxiarchis Kourelis, Prashant Kapoor, Ronald S. Go, Rahma Warsame, Nelson Leung, S. Vincent Rajkumar, Robert A. Kyle, Rajiv K. Pruthi, Morie A. Gertz, Shaji K. Kumar   +16 more
openaire   +2 more sources

Light-chain cardiac amyloidosis

Current Problems in Cancer, 2017
Cardiac amyloidosis is an underrecognized condition, in which delays to diagnosis have great implications on management options, prognosis, and morbidity. Once cardiac tissue is infiltrated by amyloid fibrils, there is a cascade of pathologic changes that can display an array of clinical manifestations, from impaired relaxation of the ventricular ...
Anit K, Mankad, Isata, Sesay, Keyur B, Shah   +2 more
openaire   +2 more sources

Macroglossia in Light-Chain Amyloidosis

New England Journal of Medicine, 2018
Macroglossia in Light-Chain Amyloidosis A 78-year-old man presented with enlargement and stiffening of the tongue. Biopsy confirmed that this finding of macroglossia was due to light-chain amyloidosis.
João Melo Alves, Natália Marto
openaire   +2 more sources

[Light chain amyloidosis].

Innere Medizin (Heidelberg, Germany), 2023
Light chain amyloidosis (AL) is a rare protein deposition disease. It is caused by a clonal plasma cell or B‑cell disease in the bone marrow. With the exception of the central nervous system, all organs can be affected by amyloid deposits. Cardiac involvement is the most frequent organ manifestation that leads to significantly increased mortality when ...
Ute, Hegenbart, Fabian, Aus dem Siepen, Stefan, Schönland   +2 more
openaire   +1 more source